Foreign Filer Report • Mar 6, 2023
Foreign Filer Report
Open in ViewerOpens in native device viewer
BioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem false
| ������� �� ��� ��"� | 2 380 |
| BIOLINE RX LTD | |
| Corporation no: 513398750 | 8688 |
| - - - | |
| Israel Securities Authority | Tel Aviv Stock Exchange | C002 ( Public ) | Reported via MAGNA: | 06/03/2023 | ||||||
| www.isa.gov.il | www.tase.co.il | Reference: | 2023-02-020287 | Time of broadcast: 12:12 12:12 |
Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
| The corporation is a foreign private issuer as defined by U.S. Securities Laws. |
Attached hereto is a report onBioLineRx Announces Clinical Trial Collaboration with Washington University School of Medicine to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
FORM_6-K_6-Mar-2023_isa.pdf
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | |
| - - - | |
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 21/02/2023 |
| Address: HaMa'ayan 2 , Modi'in 7177871 , Israel Tel: 08-6429100 , Fax: 08-6429101 | |
| E-mail address: [email protected] Company site: www.biolinerx.com | |
| Previous names of reporting entity: | |
| Name of the Signatory: Serlin Philip Adam Position of Signatory in the reporting corporation: Chief Executive Officer Name of Employer Company: | |
| Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: [email protected] 1 | |
| Israel |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.